Lorundrostat降低高危病人的血压和肾脏损伤,结果支持林业发展局在2026年初提交呈件。 Lorundrostat lowered blood pressure and kidney damage in high-risk patients, with results supporting an FDA submission by early 2026.

在2025年Kidney周上介绍的第二阶段探险-CKD和第三阶段启动-HTN试验的临床数据显示,矿物治疗药物Lorundrostat显著降低了高血压和慢性肾病患者的血压和蛋白质。 Clinical data from the Phase 2 Explore-CKD and Phase 3 Launch-HTN trials presented at Kidney Week 2025 show lorundrostat, a drug by Mineralys Therapeutics, significantly reduced blood pressure and albuminuria in patients with uncontrolled hypertension and chronic kidney disease. 该药物添加到包括SGLT2抑制剂在内的标准疗法中后,在4周内达到其主要端点,即减少9.3毫米Hg ystistoli血压,并减少25.6%。 The drug, when added to standard therapy including SGLT2 inhibitors, met its primary endpoint with a 9.3 mmHg systolic blood pressure reduction and a 25.6% decrease in albuminuria at four weeks. 它展示了有利的安全状况和持续影响,长达12周。 It demonstrated a favorable safety profile and sustained effects up to 12 weeks. 各种试验的成果支持其在不同高风险群体中的潜力,包括抗高血压、肥胖症和黑人或非裔美国人参与者群体。 Results across trials support its potential in diverse high-risk groups, including those with resistant hypertension, obesity, and Black or African American participants. 矿物公司计划在2025年底或2026年初向林业发展局提交一份新的药物申请。 Mineralys plans to file a New Drug Application with the FDA in late 2025 or early 2026.